Altimmune at Stifel 2026 Virtual Cardiometabolic Forum: liver push

Altimmune has used the Stifel 2026 Virtual Cardiometabolic Forum to outline a broader push into liver disease, centred around its dual glucagon and GLP-1 agonist pemvidutide. The company sees potential in MASH, alcohol use disorder (AUD), and alcohol-related liver disease (ALD), with Phase III MASH trial PERFORMA currently funded by its $519 million cash balance.

Management highlights pemvidutide's balanced dual mechanism and strong affinity for both receptors as setting it apart from other drugs in development. The company also sees overlap between MASH, AUD, and ALD patient populations, driven by liver pathology convergence. Altimmune is seeking non-dilutive funding, including partnerships, to support the Phase III AUD program.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.